Abstract: The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
March 14, 2023
Assignee:
Alterity Therapeutics Limited
Inventors:
Silas Bond, Penelope Jane Huggins, Jack Gordon Parsons
Abstract: The present invention relates to the use of substituted quinoline compounds for treating immunoglobulin light chain (LC) amyloidosis (AL), especially cardiotoxicity associated with immunoglobulin LC AL. In particular, the substituted quinoline compounds useful in the treatment of cardiac LC amyloidosis are 5,7-dihalo-8-hydroxyquinoline derivatives, especially 5,7-dichloro-8-hydroxyquinoline derivatives.
Type:
Grant
Filed:
June 30, 2017
Date of Patent:
June 14, 2022
Assignee:
Alterity Therapeutics Limited
Inventors:
Luisa Diomede, Mario Salmona, Giampaolo Merlini
Abstract: The present invention provides heterocyclic compounds of formula (I) that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to compounds that modulate iron and to compounds for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA).
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
October 26, 2021
Assignee:
Alterity Therapeutics Limited
Inventors:
Silas Bond, Penelope Jane Huggins, Jack Gordon Parsons
Abstract: The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds of formula (I) that modulate iron and are useful for the treatment of diseases, particularly neurological diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Alzheimer-type dementia, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and multiple system atrophy (MSA). The compounds of formula (I) being where variables are defined herein.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
March 9, 2021
Assignee:
ALTERITY THERAPEUTICS LIMITED
Inventors:
Silas Bond, Penelope Jane Huggins, Jack Gordon Parsons